Pediatric COVID-19 Vaccine Dosing Quick Reference Guide

Moderna and Pfizer-BioNTech COVID-19 Vaccine Products

### Moderna COVID-19 Vaccine Products

**2023–2024 Formula**

- **Dark blue cap/ green label**
  - 25 mcg/0.25 ml single-dose vial
  - 50 mcg/0.5 ml single-dose vial

- **Also available in a 0.5 ml single dose prefilled syringe**

### Pfizer-BioNTech COVID-19 Vaccine Products

**2023–2024 Formula**

- **Yellow cap**
  - 3 mcg/0.3 ml (dilute before use) single-dose vial

- **Blue cap**
  - 10 mcg/0.3 ml single-dose vial

- **Gray cap**
  - 30 mcg/0.3 ml single-dose vial

Also available in a 0.3 ml single dose prefilled syringe

---

### 6 months – 4 years a

#### Previously received vaccine(s)

- **Recommended 2023–2024 vaccine**
  - **Moderna dark blue cap/green label** OR **Pfizer yellow cap**

- **Dose 1**
  - 4–8 weeks after dose 1

- **Dose 2**
  - 3–8 weeks after dose 1

- **Dose 3**
  - ≥8 weeks after dose 2

#### Previously Vaccinated with Original or Bivalent

- **1 dose any Moderna**

- **2 or more doses any Moderna**

- **1 dose any Pfizer**

- **2 doses any Pfizer**

- **3 or more doses any Pfizer**

---

### 5a – 11 years

#### Previously received vaccine(s)

- **Recommended 2023–2024 vaccine**
  - **Moderna dark blue cap/green label** OR **Pfizer blue cap**

- **1 dose**
  - ≥8 weeks after last dose

#### Previously Vaccinated with Original or Bivalent

- **1 or more doses any mRNA**

- **1 dose**
  - ≥8 weeks after last dose

---

### 12 years and older

#### Previously received vaccine(s)

- **Recommended 2023–2024 vaccine**
  - **Moderna dark blue cap/blue label** OR **Pfizer gray cap**

- **1 dose**
  - ≥8 weeks after last dose

#### Previously Vaccinated with Original or Bivalent

- **1 or more doses any mRNA**

- **1 or more doses Novavax or Janssen, including in combination with any mRNA vaccine dose(s)**

- **1 dose**
  - ≥8 weeks after last dose

---

a. For children who turn 4 to 5 years during their vaccine series, follow dosing recommendations based on age at the start of the vaccine series.
Pediatric COVID-19 Vaccine Dosing Quick Reference Guide
Modern and Pfizer-BioNTech COVID-19 Vaccine Products for Individuals who are Moderately to Severely Immunocompromised

**Modern COVID-19 Vaccine Products**

**2023–2024 Formula**

- Dark blue cap/green label
  - 25 mcg/0.25 ml single-dose vial
  - 50 mcg/0.5 ml single-dose vial

- Also available in a 0.5 ml single dose prefilled syringe

**Pfizer-BioNTech COVID-19 Vaccine Products**

**2023–2024 Formula**

- Yellow cap
- Blue cap
- Gray cap

- Also available in a 0.5 ml single dose prefilled syringe

**Previously Vaccinated with Original or Bivalent**

- 1 dose any Moderna
- 2 doses any Moderna
- 1 or more doses any Moderna
- 1 dose any Pfizer
- 2 doses any Pfizer
- 3 or more doses any Pfizer

**Previously Vaccinated with Novavax**

- 1 dose
- ≥8 weeks after last dose

**Unvaccinated**

- Moderna dark blue cap/green label OR Pfizer yellow cap

**5a–11b years**

**Recommended 2023–2024 vaccine**

**Dose 1**

- 4 weeks after dose 1

**Dose 2**

- 3 weeks after dose 1

**Dose 3**

- ≥8 weeks after dose 2

**12b years and older**

**Recommended 2023–2024 vaccine**

**Dose 1**

- 4 weeks after dose 1

**Dose 2**

- ≥4 weeks after dose 2

**Dose 3**

- ≥4 weeks after dose 2

View online at aap.org/CovidVaccineGuide

Last updated September 2023

---

Notes:

a. For children who turn 4 to 5 years during their vaccine series, follow dosing recommendations based on age at the start of the vaccine series.

b. For children who turn 11 to 12 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination.

c. Individuals who are moderately to severely immunocompromised may have the option to receive one additional homologous dose of updated mRNA vaccine at least 8 weeks after the last recommended dose.

d. Additional doses may be administered at 8 week intervals, informed by clinical judgement of the healthcare provider and personal preference and circumstances.

---

For children who are moderately to severely immunocompromised have the option to receive one additional homologous dose of updated mRNA vaccine at ≥8 weeks after the last recommended dose.
### Pediatric COVID-19 Vaccine Dosing Quick Reference Guide

**Moderna COVID-19 Vaccine Products**

#### Moderna COVID-19 Vaccine Products: 2023–2024 Formula

<table>
<thead>
<tr>
<th>Dose</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose 1</td>
<td>25 mcg/0.25 ml single-dose vial</td>
</tr>
<tr>
<td>Dose 2</td>
<td>50 mcg/0.5 ml single-dose vial</td>
</tr>
</tbody>
</table>

Also available in a 0.5 ml single dose prefilled syringe.

#### 6 months – 4 years

**Previously Vaccinated with Original or Bivalent**

<table>
<thead>
<tr>
<th>Previously received vaccine(s)</th>
<th>Recommended 2023–2024 vaccine</th>
<th>Dose 1</th>
<th>Dose 2</th>
<th>Dose 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unvaccinated</td>
<td>Moderna dark blue cap/green label</td>
<td>1 dose</td>
<td>4–8 weeks after dose 1</td>
<td>≥8 weeks after last dose</td>
</tr>
<tr>
<td>Previously Vaccinated with Original or Bivalent</td>
<td>Moderna dark blue cap/green label</td>
<td>1 dose</td>
<td>4–8 weeks after dose 1</td>
<td>≥8 weeks after last dose</td>
</tr>
<tr>
<td>Previously Vaccinated with Original or Bivalent</td>
<td>Moderna dark blue cap/green label</td>
<td>1 dose</td>
<td>4–8 weeks after dose 1</td>
<td>≥8 weeks after last dose</td>
</tr>
</tbody>
</table>

#### 5a – 11b years

**Previously Vaccinated with Original or Bivalent**

<table>
<thead>
<tr>
<th>Previously received vaccine(s)</th>
<th>Recommended 2023–2024 vaccine</th>
<th>Dose 1</th>
<th>Dose 2</th>
<th>Dose 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unvaccinated</td>
<td>Moderna dark blue cap/green label</td>
<td>1 dose</td>
<td>4–8 weeks after dose 1</td>
<td>≥8 weeks after last dose</td>
</tr>
<tr>
<td>Previously Vaccinated with Original or Bivalent</td>
<td>Moderna dark blue cap/green label</td>
<td>1 dose</td>
<td>4–8 weeks after dose 1</td>
<td>≥8 weeks after last dose</td>
</tr>
<tr>
<td>Previously Vaccinated with Original or Bivalent</td>
<td>Moderna dark blue cap/green label</td>
<td>1 dose</td>
<td>4–8 weeks after dose 1</td>
<td>≥8 weeks after last dose</td>
</tr>
</tbody>
</table>

#### 12 years and older

**Previously Vaccinated with Original or Bivalent**

<table>
<thead>
<tr>
<th>Previously received vaccine(s)</th>
<th>Recommended 2023–2024 vaccine</th>
<th>Dose 1</th>
<th>Dose 2</th>
<th>Dose 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unvaccinated</td>
<td>Moderna dark blue cap/blue label</td>
<td>1 dose</td>
<td>4–8 weeks after dose 1</td>
<td>≥8 weeks after last dose</td>
</tr>
<tr>
<td>Previously Vaccinated with Original or Bivalent</td>
<td>Moderna dark blue cap/blue label</td>
<td>1 dose</td>
<td>4–8 weeks after dose 1</td>
<td>≥8 weeks after last dose</td>
</tr>
<tr>
<td>Previously Vaccinated with Original or Bivalent</td>
<td>Moderna dark blue cap/blue label</td>
<td>1 dose</td>
<td>4–8 weeks after dose 1</td>
<td>≥8 weeks after last dose</td>
</tr>
</tbody>
</table>

---

a. For children who turn 4 to 5 years during their vaccine series, follow dosing recommendations based on age at the start of the vaccine series.
b. For children who turn 11 to 12 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination.
c. Children who are moderately to severely immunocompromised have the option to receive one additional homologous dose of updated mRNA vaccine at least 8 weeks after the last recommended dose. Further additional homologous doses may be administered at ≥8 week intervals, informed by clinical judgment of the healthcare provider and personal preference and circumstances.
d. Individuals who are moderately to severely immunocompromised have the option to receive one additional dose of updated mRNA vaccine at least 8 weeks following the last recommended dose. Further additional doses may be administered at ≥8 week intervals, informed by clinical judgment of the healthcare provider and personal preference and circumstances.

View online at [aap.org/CovidVaccineGuide](http://aap.org/CovidVaccineGuide)
### Pfizer-BioNTech COVID-19 Vaccine Products

#### Pediatric COVID-19 Vaccine Dosing Quick Reference Guide

**5a – 11b years**

- **Unvaccinated**
  - 1 dose any Pfizer
- **Previously Vaccinated with Original or Bivalent**
  - 1 dose any Pfizer
  - 2 doses any Pfizer
  - 3 or more doses any Pfizer

**6 months – 4 years**

- **Unvaccinated**
  - 1 dose any Pfizer
- **Previously Vaccinated with Original or Bivalent**
  - 1 dose any Pfizer
  - 2 doses any Pfizer
  - 3 or more doses any Pfizer

**5 – 11 years**

- **Unvaccinated**
  - 1 dose any Pfizer
- **Previously Vaccinated with Original or Bivalent**
  - 1 dose any Pfizer
  - 2 doses any Pfizer
  - 3 or more doses any Pfizer

**12 years and older**

- **Unvaccinated**
  - 1 dose any Pfizer
- **Previously Vaccinated with Original or Bivalent**
  - 1 dose any Pfizer
  - 2 doses any Pfizer
  - 3 or more doses any Pfizer

---

**Pfizer-BioNTech COVID-19 Vaccine Products: 2023–2024 Formula**

<table>
<thead>
<tr>
<th>Cap Color</th>
<th>Dose 1</th>
<th>Dose 2</th>
<th>Dose 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yellow</td>
<td>3 mcg/0.3 ml (dilute before use)</td>
<td>10 mcg/0.3 ml single-dose vial</td>
<td>30 mcg/0.3 ml single-dose vial</td>
</tr>
<tr>
<td>Blue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gray</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Also available in a 0.3 ml single dose prefilled syringe.

---

**Unvaccinated**

- For children who turn 4 to 5 years during their vaccine series, follow dosing recommendations based on age at the start of the vaccine series.
- For children who turn 11 to 12 years during their vaccine series, follow dosing recommendations based on age at the time of vaccination.
- Children who are moderately to severely immunocompromised have the option to receive one additional homologous dose of updated mRNA vaccine at least 8 weeks after the last recommended dose.
- Further additional homologous doses may be administered at ≥8 week intervals, informed by clinical judgment of the health care provider and personal preference and circumstances.
- Individuals who are moderately to severely immunocompromised have the option to receive one additional dose of updated mRNA vaccine at least 8 weeks following the last recommended dose.
- Further additional doses may be administered at ≥8 week intervals, informed by clinical judgement of the healthcare provider and personal preference and circumstances.

---

**View online at aap.org/CovidVaccineGuide**

Last updated September 2023
**Novavax COVID-19 Vaccine**

**Novavax COVID-19 Vaccine Product**
- Dark blue cap
- 5 mcg/0.5 ml

**Moderna COVID-19 Vaccine Products**
- Dark blue cap/blue label
  - Also available in a 0.5 ml single-dose vial
- 50 mcg/0.5 ml single-dose vial

**Pfizer-BioNTech COVID-19 Vaccine Products**
- Gray cap
  - Also available in a 0.3 ml single-dose prefilled syringe
- 30 mcg/0.3 ml single-dose vial

---

### Moderately to Severely Immunocompromised Individuals

**12–17 years**

<table>
<thead>
<tr>
<th>Previously received vaccine(s)</th>
<th>Recommended vaccine</th>
<th>Unvaccinated</th>
<th>Previously Vaccinated with Original or Bivalent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previously received vaccine(s)</td>
<td>Recommended vaccine</td>
<td>Novavax dark blue cap</td>
<td>1 or more doses of Novavax</td>
</tr>
<tr>
<td>1 dose</td>
<td>Moderna dark blue cap/blue label</td>
<td>Novavax dark blue cap</td>
<td>Moderna dark blue cap/blue label</td>
</tr>
<tr>
<td>OR</td>
<td>Pfizer gray cap</td>
<td>3–8 weeks after last dose</td>
<td>3–8 weeks after last dose</td>
</tr>
</tbody>
</table>

**18 years and older**

<table>
<thead>
<tr>
<th>Previously received vaccine(s)</th>
<th>Recommended vaccine</th>
<th>Unvaccinated</th>
<th>Previously Vaccinated with Original or Bivalent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previously received vaccine(s)</td>
<td>Recommended vaccine</td>
<td>Novavax dark blue cap</td>
<td>1 or more doses of Novavax</td>
</tr>
<tr>
<td>1 dose</td>
<td>Moderna dark blue cap/blue label</td>
<td>Novavax dark blue cap</td>
<td>Moderna dark blue cap/blue label</td>
</tr>
<tr>
<td>OR</td>
<td>Pfizer gray cap</td>
<td>3–8 weeks after last dose</td>
<td>3–8 weeks after last dose</td>
</tr>
</tbody>
</table>

---

**e.** In limited situations where mRNA vaccine is contraindicated, unavailable, or declined and a booster dose has not been previously administered.

**f.** Individuals who are moderately to severely immunocompromised have the option to receive one additional dose of updated mRNA vaccine at least 8 weeks following the last recommended dose. Further additional doses may be administered at ≥8 week intervals, informed by clinical judgement of the healthcare provider and personal preference and circumstances.

*View online at aap.org/CovidVaccineGuide*

*Last updated September 2023*